Cargando…
PB2225: A RANDOMIZED OPEN-LABEL, PHASE 3 STUDY OF IMETELSTAT VS BEST AVAILABLE THERAPY IN INTERMEDIATE-2 OR HIGH-RISK MYELOFIBROSIS RELAPSED/REFRACTORY TO JAK INHIBITOR (IMPACTMF)
| Autores principales: | , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429542/ http://dx.doi.org/10.1097/01.HS9.0000975644.99899.f4 |
| _version_ | 1785090740770045952 |
|---|---|
| author | Mascarenhas, John Harrison, Claire Kiladjian, Jean-Jacques Sockel, Katja Vannucchi, Alessandro Berry, Tymara Redding, Denise Sherman, Laurie Dougherty, Souria Peng, Lixian Sun, Libo Huang, Fei Wan, Ying Rodolf, Vivian Ho, Judy Navada, Shyamala Komrokji, Rami S. |
| author_facet | Mascarenhas, John Harrison, Claire Kiladjian, Jean-Jacques Sockel, Katja Vannucchi, Alessandro Berry, Tymara Redding, Denise Sherman, Laurie Dougherty, Souria Peng, Lixian Sun, Libo Huang, Fei Wan, Ying Rodolf, Vivian Ho, Judy Navada, Shyamala Komrokji, Rami S. |
| author_sort | Mascarenhas, John |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10429542 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104295422023-08-17 PB2225: A RANDOMIZED OPEN-LABEL, PHASE 3 STUDY OF IMETELSTAT VS BEST AVAILABLE THERAPY IN INTERMEDIATE-2 OR HIGH-RISK MYELOFIBROSIS RELAPSED/REFRACTORY TO JAK INHIBITOR (IMPACTMF) Mascarenhas, John Harrison, Claire Kiladjian, Jean-Jacques Sockel, Katja Vannucchi, Alessandro Berry, Tymara Redding, Denise Sherman, Laurie Dougherty, Souria Peng, Lixian Sun, Libo Huang, Fei Wan, Ying Rodolf, Vivian Ho, Judy Navada, Shyamala Komrokji, Rami S. Hemasphere Publication Only Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10429542/ http://dx.doi.org/10.1097/01.HS9.0000975644.99899.f4 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Publication Only Mascarenhas, John Harrison, Claire Kiladjian, Jean-Jacques Sockel, Katja Vannucchi, Alessandro Berry, Tymara Redding, Denise Sherman, Laurie Dougherty, Souria Peng, Lixian Sun, Libo Huang, Fei Wan, Ying Rodolf, Vivian Ho, Judy Navada, Shyamala Komrokji, Rami S. PB2225: A RANDOMIZED OPEN-LABEL, PHASE 3 STUDY OF IMETELSTAT VS BEST AVAILABLE THERAPY IN INTERMEDIATE-2 OR HIGH-RISK MYELOFIBROSIS RELAPSED/REFRACTORY TO JAK INHIBITOR (IMPACTMF) |
| title | PB2225: A RANDOMIZED OPEN-LABEL, PHASE 3 STUDY OF IMETELSTAT VS BEST AVAILABLE THERAPY IN INTERMEDIATE-2 OR HIGH-RISK MYELOFIBROSIS RELAPSED/REFRACTORY TO JAK INHIBITOR (IMPACTMF) |
| title_full | PB2225: A RANDOMIZED OPEN-LABEL, PHASE 3 STUDY OF IMETELSTAT VS BEST AVAILABLE THERAPY IN INTERMEDIATE-2 OR HIGH-RISK MYELOFIBROSIS RELAPSED/REFRACTORY TO JAK INHIBITOR (IMPACTMF) |
| title_fullStr | PB2225: A RANDOMIZED OPEN-LABEL, PHASE 3 STUDY OF IMETELSTAT VS BEST AVAILABLE THERAPY IN INTERMEDIATE-2 OR HIGH-RISK MYELOFIBROSIS RELAPSED/REFRACTORY TO JAK INHIBITOR (IMPACTMF) |
| title_full_unstemmed | PB2225: A RANDOMIZED OPEN-LABEL, PHASE 3 STUDY OF IMETELSTAT VS BEST AVAILABLE THERAPY IN INTERMEDIATE-2 OR HIGH-RISK MYELOFIBROSIS RELAPSED/REFRACTORY TO JAK INHIBITOR (IMPACTMF) |
| title_short | PB2225: A RANDOMIZED OPEN-LABEL, PHASE 3 STUDY OF IMETELSTAT VS BEST AVAILABLE THERAPY IN INTERMEDIATE-2 OR HIGH-RISK MYELOFIBROSIS RELAPSED/REFRACTORY TO JAK INHIBITOR (IMPACTMF) |
| title_sort | pb2225: a randomized open-label, phase 3 study of imetelstat vs best available therapy in intermediate-2 or high-risk myelofibrosis relapsed/refractory to jak inhibitor (impactmf) |
| topic | Publication Only |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429542/ http://dx.doi.org/10.1097/01.HS9.0000975644.99899.f4 |
| work_keys_str_mv | AT mascarenhasjohn pb2225arandomizedopenlabelphase3studyofimetelstatvsbestavailabletherapyinintermediate2orhighriskmyelofibrosisrelapsedrefractorytojakinhibitorimpactmf AT harrisonclaire pb2225arandomizedopenlabelphase3studyofimetelstatvsbestavailabletherapyinintermediate2orhighriskmyelofibrosisrelapsedrefractorytojakinhibitorimpactmf AT kiladjianjeanjacques pb2225arandomizedopenlabelphase3studyofimetelstatvsbestavailabletherapyinintermediate2orhighriskmyelofibrosisrelapsedrefractorytojakinhibitorimpactmf AT sockelkatja pb2225arandomizedopenlabelphase3studyofimetelstatvsbestavailabletherapyinintermediate2orhighriskmyelofibrosisrelapsedrefractorytojakinhibitorimpactmf AT vannucchialessandro pb2225arandomizedopenlabelphase3studyofimetelstatvsbestavailabletherapyinintermediate2orhighriskmyelofibrosisrelapsedrefractorytojakinhibitorimpactmf AT berrytymara pb2225arandomizedopenlabelphase3studyofimetelstatvsbestavailabletherapyinintermediate2orhighriskmyelofibrosisrelapsedrefractorytojakinhibitorimpactmf AT reddingdenise pb2225arandomizedopenlabelphase3studyofimetelstatvsbestavailabletherapyinintermediate2orhighriskmyelofibrosisrelapsedrefractorytojakinhibitorimpactmf AT shermanlaurie pb2225arandomizedopenlabelphase3studyofimetelstatvsbestavailabletherapyinintermediate2orhighriskmyelofibrosisrelapsedrefractorytojakinhibitorimpactmf AT doughertysouria pb2225arandomizedopenlabelphase3studyofimetelstatvsbestavailabletherapyinintermediate2orhighriskmyelofibrosisrelapsedrefractorytojakinhibitorimpactmf AT penglixian pb2225arandomizedopenlabelphase3studyofimetelstatvsbestavailabletherapyinintermediate2orhighriskmyelofibrosisrelapsedrefractorytojakinhibitorimpactmf AT sunlibo pb2225arandomizedopenlabelphase3studyofimetelstatvsbestavailabletherapyinintermediate2orhighriskmyelofibrosisrelapsedrefractorytojakinhibitorimpactmf AT huangfei pb2225arandomizedopenlabelphase3studyofimetelstatvsbestavailabletherapyinintermediate2orhighriskmyelofibrosisrelapsedrefractorytojakinhibitorimpactmf AT wanying pb2225arandomizedopenlabelphase3studyofimetelstatvsbestavailabletherapyinintermediate2orhighriskmyelofibrosisrelapsedrefractorytojakinhibitorimpactmf AT rodolfvivian pb2225arandomizedopenlabelphase3studyofimetelstatvsbestavailabletherapyinintermediate2orhighriskmyelofibrosisrelapsedrefractorytojakinhibitorimpactmf AT hojudy pb2225arandomizedopenlabelphase3studyofimetelstatvsbestavailabletherapyinintermediate2orhighriskmyelofibrosisrelapsedrefractorytojakinhibitorimpactmf AT navadashyamala pb2225arandomizedopenlabelphase3studyofimetelstatvsbestavailabletherapyinintermediate2orhighriskmyelofibrosisrelapsedrefractorytojakinhibitorimpactmf AT komrokjiramis pb2225arandomizedopenlabelphase3studyofimetelstatvsbestavailabletherapyinintermediate2orhighriskmyelofibrosisrelapsedrefractorytojakinhibitorimpactmf |